CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 40.94 USD 1.14% Market Closed
Market Cap: 3.5B USD
Have any thoughts about
CRISPR Therapeutics AG?
Write Note
CRSP
/
Balance Sheet
/
Other Long-Term Assets

CRISPR Therapeutics AG
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CRISPR Therapeutics AG
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
CRISPR Therapeutics AG
NASDAQ:CRSP
Other Long-Term Assets
$27.4m
CAGR 3-Years
8%
CAGR 5-Years
43%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Other Long-Term Assets
$711k
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Other Long-Term Assets
CHf13.8m
CAGR 3-Years
236%
CAGR 5-Years
62%
CAGR 10-Years
53%
Kuros Biosciences AG
SIX:KURN
Other Long-Term Assets
CHf209k
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CRISPR Therapeutics AG
Glance View

Market Cap
3.5B USD
Industry
Biotechnology

CRISPR Therapeutics AG is at the forefront of revolutionizing modern medicine through gene-editing technology. Founded on the groundbreaking research of CRISPR-Cas9, a tool that allows scientists to precisely alter an organism’s DNA, the company has swiftly emerged as a leader in the biotech arena. Situated in Switzerland, with significant operations in the United States, CRISPR Therapeutics aims to translate this cutting-edge science into transformative therapies. Its portfolio highlights collaborative efforts with other industry giants to develop treatments for serious genetic diseases, such as its flagship program targeting sickle cell disease and beta-thalassemia. By leveraging its proprietary CRISPR platform, the company focuses on developing gene-based medicines that address the root causes of illnesses, marking a departure from traditional symptom management to potentially groundbreaking cures. The business model of CRISPR Therapeutics is both innovative and strategic. Monetization is achieved through a blend of partnerships, licensing agreements, and direct therapeutic development. The company collaborates with various pharmaceutical entities, creating a network of shared knowledge and resources that accelerates the commercialization of therapies. These alliances facilitate shared risk and reward, allowing CRISPR Therapeutics to generate revenue while advancing its research and development pipeline. Moreover, the successful progression of any internally-developed therapies into approved treatments has the potential to unlock significant financial returns, both from sales and potential royalties. True to its visionary roots, CRISPR Therapeutics not only pursues immediate financial success but also seeks to redefine the landscape of genetic medicine with the long-term goal of delivering curative treatments for numerous genetic conditions.

CRSP Intrinsic Value
100.48 USD
Undervaluation 59%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is CRISPR Therapeutics AG's Other Long-Term Assets?
Other Long-Term Assets
27.4m USD

Based on the financial report for Sep 30, 2024, CRISPR Therapeutics AG's Other Long-Term Assets amounts to 27.4m USD.

What is CRISPR Therapeutics AG's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
43%

Over the last year, the Other Long-Term Assets growth was 97%. The average annual Other Long-Term Assets growth rates for CRISPR Therapeutics AG have been 8% over the past three years , 43% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.